Cargando…
Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein
During the past two decades, the world has witnessed the emergence of various SARS-CoV-2 variants with distinct mutational profiles influencing the global health, economy, and clinical aspects of the COVID-19 pandemic. These variants or mutants have raised major concerns regarding the protection pro...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498999/ https://www.ncbi.nlm.nih.gov/pubmed/36142242 http://dx.doi.org/10.3390/ijms231810315 |
_version_ | 1784794900051525632 |
---|---|
author | Khan, Salman Ali Khan, Alamgir Zia, Komal Shawish, Ihab Barakat, Assem Ul-Haq, Zaheer |
author_facet | Khan, Salman Ali Khan, Alamgir Zia, Komal Shawish, Ihab Barakat, Assem Ul-Haq, Zaheer |
author_sort | Khan, Salman Ali |
collection | PubMed |
description | During the past two decades, the world has witnessed the emergence of various SARS-CoV-2 variants with distinct mutational profiles influencing the global health, economy, and clinical aspects of the COVID-19 pandemic. These variants or mutants have raised major concerns regarding the protection provided by neutralizing monoclonal antibodies and vaccination, rates of virus transmission, and/or the risk of reinfection. The newly emerged Omicron, a genetically distinct lineage of SARS-CoV-2, continues its spread in the face of rising vaccine-induced immunity while maintaining its replication fitness. Efforts have been made to improve the therapeutic interventions and the FDA has issued Emergency Use Authorization for a few monoclonal antibodies and drug treatments for COVID-19. However, the current situation of rapidly spreading Omicron and its lineages demands the need for effective therapeutic interventions to reduce the COVID-19 pandemic. Several experimental studies have indicated that the FDA-approved monoclonal antibodies are less effective than antiviral drugs against the Omicron variant. Thus, in this study, we aim to identify antiviral compounds against the Spike protein of Omicron, which binds to the human angiotensin-converting enzyme 2 (ACE2) receptor and facilitates virus invasion. Initially, docking-based virtual screening of the in-house database was performed to extract the potential hit compounds against the Spike protein. The obtained hits were optimized by DFT calculations to determine the electronic properties and molecular reactivity of the compounds. Further, MD simulation studies were carried out to evaluate the dynamics of protein–ligand interactions at an atomistic level in a time-dependent manner. Collectively, five compounds (AKS-01, AKS-02, AKS-03, AKS-04, and AKS-05) with diverse scaffolds were identified as potential hits against the Spike protein of Omicron. Our study paves the way for further in vitro and in vivo studies. |
format | Online Article Text |
id | pubmed-9498999 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94989992022-09-23 Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein Khan, Salman Ali Khan, Alamgir Zia, Komal Shawish, Ihab Barakat, Assem Ul-Haq, Zaheer Int J Mol Sci Article During the past two decades, the world has witnessed the emergence of various SARS-CoV-2 variants with distinct mutational profiles influencing the global health, economy, and clinical aspects of the COVID-19 pandemic. These variants or mutants have raised major concerns regarding the protection provided by neutralizing monoclonal antibodies and vaccination, rates of virus transmission, and/or the risk of reinfection. The newly emerged Omicron, a genetically distinct lineage of SARS-CoV-2, continues its spread in the face of rising vaccine-induced immunity while maintaining its replication fitness. Efforts have been made to improve the therapeutic interventions and the FDA has issued Emergency Use Authorization for a few monoclonal antibodies and drug treatments for COVID-19. However, the current situation of rapidly spreading Omicron and its lineages demands the need for effective therapeutic interventions to reduce the COVID-19 pandemic. Several experimental studies have indicated that the FDA-approved monoclonal antibodies are less effective than antiviral drugs against the Omicron variant. Thus, in this study, we aim to identify antiviral compounds against the Spike protein of Omicron, which binds to the human angiotensin-converting enzyme 2 (ACE2) receptor and facilitates virus invasion. Initially, docking-based virtual screening of the in-house database was performed to extract the potential hit compounds against the Spike protein. The obtained hits were optimized by DFT calculations to determine the electronic properties and molecular reactivity of the compounds. Further, MD simulation studies were carried out to evaluate the dynamics of protein–ligand interactions at an atomistic level in a time-dependent manner. Collectively, five compounds (AKS-01, AKS-02, AKS-03, AKS-04, and AKS-05) with diverse scaffolds were identified as potential hits against the Spike protein of Omicron. Our study paves the way for further in vitro and in vivo studies. MDPI 2022-09-07 /pmc/articles/PMC9498999/ /pubmed/36142242 http://dx.doi.org/10.3390/ijms231810315 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Khan, Salman Ali Khan, Alamgir Zia, Komal Shawish, Ihab Barakat, Assem Ul-Haq, Zaheer Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein |
title | Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein |
title_full | Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein |
title_fullStr | Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein |
title_full_unstemmed | Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein |
title_short | Cheminformatics-Based Discovery of Potential Chemical Probe Inhibitors of Omicron Spike Protein |
title_sort | cheminformatics-based discovery of potential chemical probe inhibitors of omicron spike protein |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9498999/ https://www.ncbi.nlm.nih.gov/pubmed/36142242 http://dx.doi.org/10.3390/ijms231810315 |
work_keys_str_mv | AT khansalmanali cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein AT khanalamgir cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein AT ziakomal cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein AT shawishihab cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein AT barakatassem cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein AT ulhaqzaheer cheminformaticsbaseddiscoveryofpotentialchemicalprobeinhibitorsofomicronspikeprotein |